Yinhua CSI Innovative Drugs Industry ETF(159992) falls 3.08%, with a share increase of 70.80 million units over the past week

NewTimeSpace (newtimespace.com) News, as of 13:35 on July 24, 2026, Yinhua Innovative Drug ETF (159992) fell 3.08%, with the latest price at 0.85 yuan. Over a longer time frame, as of July 23, 2026, the ETF accumulated a gain of 5.79% over the past two weeks, ranking 2/7 among comparable funds.

In terms of liquidity, Yinhua Innovative Drug ETF recorded an intraday turnover rate of 4.21% and a trading volume of 743 million yuan. Over a longer time frame, as of July 23, the ETF's average daily trading volume over the past month reached 1.476 billion yuan, ranking first among comparable funds.

In terms of scale, Yinhua Innovative Drug ETF saw a significant increase of 751 million yuan in scale over the past week, with the new scale increase ranking 1/7 among comparable funds. (Data source: Wind)

In terms of shares, Yinhua Innovative Drug ETF experienced a significant increase of 70.80 million units in share count over the past week, with the new share increase ranking 3/7 among comparable funds. (Data source: Wind)

In terms of capital flows, the latest net outflow from Yinhua Innovative Drug ETF was 62.3674 million yuan. Over a longer time frame, within the past five trading days, there were four days of net inflow, attracting a total of 451 million yuan, with an average daily net inflow of 90.2122 million yuan. (Data source: Wind)

Data shows that leveraged funds are continuously positioning. Yinhua Innovative Drug ETF recorded a net margin financing purchase of 2.7024 million yuan month-to-date, with the latest margin financing balance standing at 684 million yuan. (Data source: Wind)

As of July 23, the net value of Yinhua Innovative Drug ETF rose by 1.65% over the past six months, ranking in the top 3 among comparable funds. From the perspective of return capability, as of July 23, 2026, since its inception, the ETF achieved a highest single-month return of 22.79%, a longest streak of consecutive up months of 4 months, a maximum cumulative gain during that streak of 53.27%, and an average return of 6.43% in up months. As of July 23, 2026, the ETF's annualized excess return over its benchmark for the past three months was 4.65%, ranking in the top 3/7 among comparable funds.

In terms of drawdown, as of July 23, 2026, Yinhua Innovative Drug ETF recorded a drawdown of 0.18% relative to its benchmark over the past six months. The number of days to recover after the drawdown was 28 days, the fastest recovery among comparable funds.

In terms of fees, Yinhua Innovative Drug ETF has a management fee rate of 0.50% and a custodian fee rate of 0.05%.

Yinhua Innovative Drug ETF closely tracks the CSI Innovative Drug Industry Index. The CSI Innovative Drug Industry Index selects no more than 50 of the most representative listed company securities whose main businesses involve innovative drug research and development as index constituents, in order to reflect the overall performance of the securities of listed companies in the innovative drug industry.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.